Obesity Cell Models for Research

Obesity is a global epidemic. According to the World Health Organization (WHO), worldwide obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults were overweight, of whom over 650 million were obese. Obesity is a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular disease, and certain cancers. The economic burden is substantial, with healthcare costs and lost productivity. Obesity is defined by a body mass index (BMI) of 30 or higher. The prevalence is increasing in both developed and developing countries, affecting all age groups. The clinical impact includes reduced quality of life and increased mortality. Research is crucial to understand the underlying mechanisms and develop effective therapies.

Obesity is a complex, multifactorial disease involving genetic, environmental, and behavioral factors. It is an ideal model for mechanistic studies because of its well-characterized metabolic pathways and the availability of numerous in vitro and in vivo models. Key research areas include energy homeostasis, adipocyte biology, and the role of the central nervous system in regulating appetite. Public datasets, such as those from the Gene Expression Omnibus (GEO), provide extensive transcriptomic and epigenetic data from adipose tissue and hypothalamus. Open questions include the identification of novel drug targets, understanding the heterogeneity of obesity, and developing personalized treatments. Gene-edited cell models are essential for functional validation of candidate genes and pathways.

Obesity is not a cancer, but it is a risk factor for several cancers. However, the molecular pathogenesis of obesity itself involves key pathways:

• • Leptin-Melanocortin Pathway: Leptin, secreted by adipose tissue, binds to the leptin receptor (LEPR) in the hypothalamus, activating pro-opiomelanocortin (POMC) neurons and inhibiting agouti-related peptide (AgRP) neurons. This reduces appetite and increases energy expenditure.
• • Insulin Signaling: Insulin regulates glucose homeostasis and lipid metabolism. Insulin resistance in obesity leads to hyperinsulinemia and metabolic dysfunction.
• • Adipogenesis and Lipid Metabolism: Peroxisome proliferator-activated receptor gamma (PPARG) and CCAAT/enhancer-binding protein alpha (CEBPA) are master regulators of adipocyte differentiation. Dysregulation leads to adipocyte hypertrophy and inflammation.
• • Inflammatory Pathways: Obesity is associated with chronic low-grade inflammation, involving tumor necrosis factor alpha (TNF) and interleukin-6 (IL6), which contribute to insulin resistance.

Obesity is not typically characterized by somatic mutations like cancer, but genetic variants contribute to susceptibility. Common variants in genes such as FTO, MC4R, and LEPR are associated with obesity. The following table summarizes key genes with their frequency and functional effect based on population studies (data from NCBI and ClinVar):

Obesity involves deregulation of several signaling networks:

• • Leptin-Melanocortin Network: Key nodes include LEPR, JAK2, STAT3, POMC, MC4R, and AgRP. Disruption leads to altered energy balance.
• • Insulin Signaling Network: Involves insulin receptor (INSR), IRS1, PI3K, AKT, and FOXO1. Insulin resistance impairs glucose uptake and promotes lipolysis.
• • Adipokine Network: Adipose tissue secretes adipokines such as leptin, adiponectin, and resistin. Imbalance contributes to inflammation and metabolic dysfunction.
• • Inflammatory Signaling: NF-kB and JNK pathways are activated in obesity, leading to cytokine production and insulin resistance.

Common cell lines used in obesity research include:

Organoids, such as adipose organoids, are three-dimensional cultures that better mimic the in vivo microenvironment. They can be used to study cell-cell interactions and drug responses.

Animal models are essential for studying obesity in a whole-organism context:

• • Diet-Induced Obesity (DIO) Models: Mice or rats fed a high-fat diet to induce obesity. These models mimic human obesity and are used for drug testing.
• • Genetic Models: ob/ob mice (leptin deficiency) and db/db mice (leptin receptor deficiency) are classic models of severe obesity. These are spontaneous mutations.
• • Genetically Engineered Mouse Models (GEMM): Knockout or knock-in mice for genes like MC4R, POMC, and LEPR. These models help study specific pathways.
• • Patient-Derived Xenografts (PDX): Not commonly used for obesity, but can be used to study obesity-related cancers.

CRISPR-based gene editing has revolutionized obesity research by enabling the creation of isogenic cell lines with precise genetic modifications. These models are crucial for functional validation of genes associated with obesity. Examples include:

• • Leptin Receptor (LEPR) Knockout Cell Lines: These cells lack functional LEPR, mimicking the db/db mutation. They are used to study leptin signaling and identify downstream targets.
• • MC4R Knock-in Cell Lines: Introduction of specific MC4R mutations (e.g., V103I) allows study of receptor function and drug response.
• • POMC Knockout Cell Lines: These cells lack POMC, affecting melanocortin signaling. They are used to study appetite regulation.
• • Adipocyte Reporter Lines: CRISPR-engineered cell lines with fluorescent reporters under the control of adipogenic promoters (e.g., PPARG) enable real-time monitoring of differentiation.

These gene-edited cell models are commercially available from various sources, ensuring sequence verification and quality. They accelerate research by providing consistent and reproducible models for drug discovery and functional genomics.

Gene-edited cell lines are used to validate the function of genes implicated in obesity. For example:

• • Knockout of FTO in adipocytes can reveal its role in adipogenesis and energy metabolism.
• • Knock-in of a mutant LEPR can confirm the impact of specific mutations on signaling.
• • CRISPR screens using pooled libraries can identify genes that regulate lipid accumulation or insulin sensitivity.

Isogenic cell line pairs (wild-type vs. knockout) are powerful tools for drug screening. For example:

• • Screening compounds that activate MC4R in a knock-in cell line with a specific mutation can identify drugs that overcome resistance.
• • Testing drugs that target leptin signaling in LEPR knockout cells can reveal off-target effects.
• • Resistance to anti-obesity drugs can be modeled by chronic exposure of cells to the drug and then identifying genetic changes that confer resistance.

CRISPR-based synthetic lethality screens can identify genes that are essential in obesity-related pathways. For example:

• • In adipocytes, knocking out genes involved in lipid metabolism may reveal synthetic lethal partners that could be targeted therapeutically.
• • Gene-edited cell models can be used to identify biomarkers of drug response or disease progression.